Companies › Autobahn Therapeutics
1 active drug program in 2 registered trials: 2 Phase 2; Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABX-002 | – | Phase 2 | Bipolar Disorder Depression; Major Depressive Disorder | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06869187 | ABX-002 | Phase 2 | Bipolar Disorder Depression | Psychiatry | Apr 2026 |
| NCT06633016 | ABX-002 | Phase 2 | Major Depressive Disorder | Psychiatry | Jun 2026 |
No annotated target.
–
NeuroRx Bazelet Nehushtan atai Therapeutics Arialys Australia Apsen Farmaceutica
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.